MedCity News March 24, 2024
Rohin K. Iyer and Robert Brackner

The “holy grail” of ATMP-based treatments is to provide cures for some of the world’s most debilitating disease states, but for this to occur, a unified front is needed to democratize these therapies – collaboration from industry, academia, supply chain and, indeed, clinicians and hospitals is paramount to ensuring safe manufacturing and transit.

In laboratories around the globe, scientists are diligently researching the limitless potential of advanced therapeutic medicinal products (ATMPs). These groundbreaking therapies are changing the face of healthcare by harnessing the potential of the human body for healing. Using cells, proteins, antibodies, tissues and nucleic acids as “living” therapies is simultaneously promising, but also brings unique challenges from a manufacturing, supply chain, and patient treatment standpoint. The advent...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Provider, Supply Chain, Technology
The AI Software Supply Chain Is A Dumpster Fire: Here's What Companies Can Do About It
Supply chain challenges in 2025: 5 things to know
As Supply Chains Go Digital, Cybersecurity Must be Strongest Link
Digital twins: The key to unlocking end-to-end supply chain growth
Why Supply Chain Technology Keeps Failing—And How To Fix It

Share This Article